��������Ƶ

Our mission to care, to teach, to discover is achieved daily through a culture of exceptionalism. Our values of performance, respect, integrity, diversity, and excellence (PRIDE) influence the way we show up each and every day for our patients, our students, and our communities.

In 2024, ��������Ƶ Health’s revenue was $14.2 billion, including more than $5 billion in philanthropy since 2007.

A Reputation for Excellence

��������Ƶ has been ranked the No. 1 comprehensive academic medical center for quality care in the United States for three years in a row by Vizient Inc., the nation’s largest healthcare performance improvement organization. Our hospitals in Manhattan and Brooklyn and on Long Island have received straight A’s for safety by The Leapfrog Group. Because of our commitment to continuous improvement and delivering safe, high-quality care, we have received The Gold Seal of Approval® by The Joint Commission. We are among the best hospitals in the U.S. according to U.S. News and World Report’s 2024–25 “Best Hospitals Honor Roll,” earning top 20 rankings in 13 specialties, 11 of which are in the top 10. Rusk Rehabilitation is consistently ranked the No. 1 rehabilitation program in New York State and one of the top five in the country by U.S. News & World Report. The Centers for Medicare and Medicaid Services has awarded ��������Ƶ a five-star rating for quality. We are the only health system* in New York to receive Magnet® Recognition across all our hospitals for excellence in nursing and quality patient care from the American Nurses Credentialing Center, an honor achieved by only 9.8 percent of hospitals in the United States.

Our History

��������Ƶ was founded as the Medical College of New York University in 1841 by Valentine Mott, MD, the premier surgeon of his day, and five other eminent physicians and scientists. ��������Ƶ’s first hospital, known as University Hospital, was established in 1948, a century after its Medical College. In 1963, a newly acquired site in midtown Manhattan became the home of University Hospital’s new 18-story building. Adopting a novel concept in healthcare, the more than 350-bed acute-care facility—now Tisch Hospital—partnered with outpatient practices to speed the translation of scientific discovery to the clinic and allow physicians to conduct academic and research activities while maintaining private practice.

The first hospital to merge with our institution was the Hospital for Joint Diseases, now known as ��������Ƶ Orthopedic Hospital. The 225-bed hospital, a long-time affiliate, became ��������Ƶ’s dedicated orthopedic hospital in 2006. In 2018, a new Science Building, ��������Ƶ’s largest research facility, united teams of investigators previously housed in several facilities. That same year, the Helen L. and Martin S. Kimmel Pavilion opened and became the only inpatient facility in New York City with exclusively private rooms. Of its 374 beds, 68 are in Hassenfeld Children’s Hospital at ��������Ƶ, the city’s first new children’s hospital in nearly 15 years.

In 2016, we acquired Lutheran Medical Center, a 444-bed acute-care hospital in southwest Brooklyn. Within several years, ��������Ƶ Hospital—Brooklyn, as it was renamed, benefited so greatly from our health system’s infusion of resources and expertise that it now qualifies as one of the safest hospitals, not only in New York City, but also in the nation. The only five-star hospital in Brooklyn, as ranked by CMS, ��������Ƶ Hospital—Brooklyn is the first and only hospital in Brooklyn to receive Magnet recognition for excellence in nursing and quality patient care.

In 2019, ��������Ƶ extended its reach once again, this time to Nassau County on Long Island. Our acquisition of Winthrop University Hospital, a 591-bed acute-care hospital in Mineola, enlarged the ��������Ƶ system by 25 percent. Thanks to the same rigorous quality control measures implemented at our Brooklyn hospital, ��������Ƶ Hospital—Long Island, as it was renamed, saw its average length of stay, a key measure of patient safety, decrease by nearly 20 percent in just two years.

Groundbreaking Medicine

In addition to providing our patients the best quality and safety outcomes, our clinicians and researchers have set new standards for the diagnosis and treatment of diseases and have made or contributed to breakthroughs in biomedical science.

In 2015, a team of surgeons led by Eduardo D. Rodriguez, MD, DDS, Helen L. Kimmel Professor of Reconstructive Plastic Surgery and chair of ��������Ƶ’s , performed the most extensive face transplant to date, followed in 2020 by the world’s first successful face and double-hand transplant, and in 2023 by the world’s first whole-eye and partial-face transplant.

In 2021, a team of surgeons led by Robert Montgomery, MD, DPhil, director of the ��������Ƶ Transplant Institute, the H. Leon Pachter, MD, Professor of Surgery, and chair of the , performed the first investigational transplant of a kidney grown in a genetically altered pig to a brain-dead person whose bodily functions were sustained by mechanical support. In separate investigational procedures performed in June and July 2022, surgeons led by Dr. Montgomery successfully transplanted hearts from genetically altered pigs into brain-dead patients, marking the latest advance toward addressing the nationwide organ shortage and developing a clinical protocol that would provide an alternative supply of organs for people with life-threatening heart disease. In 2024, Dr. Montgomery and his team of surgeons performed the world’s first combined implant of a mechanical heart pump and transplant of a kidney from a genetically modified pig, and later in the year, the first transplantation of a pig kidney with 10 gene edits.

In 2024, Stephanie H. Chang, MD, associate professor in the at NYU Grossman School of Medicine and the surgical director of the Lung Transplant Program at ��������Ƶ Transplant Institute, achieved a historic milestone by leading the nation’s first fully robotic lung transplant. Later that year, she further advanced medical innovation by heading the team that performed the world’s first double lung transplant using this robotic technology.

Transforming Medical Education

has spearheaded innovations that have not only transformed the training of our own medical students but also inspired educational reforms at other medical schools nationwide. In 2013, the school began offering an accelerated for select students, an initiative designed to ease the financial burden of medical school and launch medical careers one year earlier than traditional students. The program made ��������Ƶ the first nationally ranked academic medical center in the United States to enable graduates to pursue a career in either primary care or the medical specialty of their choice in three years.

In 2010, NYU Grossman School of Medicine introduced its Curriculum for the 21st Century (C21). This curriculum changes the historic approach of teaching by introducing medical students to specific areas of medicine, or “pillars,” on their very first day to foster student knowledge both through a study of the scientific underpinnings of a disease and, at the same time, through direct patient care—from the basic sciences to bedside application and back again. C21 allows every student to complete their graduation requirements in three years and pursue residency training anywhere in the country. Alternatively, students may elect to stay for an optional fourth year to pursue research or one of several dual degrees that combine a medical degree with a master’s degree.

Then in 2018—and through a groundswell of generosity from hundreds of alumni, ��������Ƶ trustees, and other scholarship supporters—the school once again made history. NYU Grossman School of Medicine became the first top-ranked medical school in the nation to provide to all new and current students, a bold strategy to reduce the staggering debt incurred by medical students due to the ever-rising cost of their education. The following year, NYU School of Medicine was renamed NYU Grossman School of Medicine in honor of the landmark educational achievements and visionary leadership of Dean and CEO Robert I. Grossman, MD, who vaulted the school to national renown. Today, one in six medical school applicants nationwide set their sights on NYU Grossman School of Medicine.

In 2019, ��������Ƶ expanded its medical student training when it launched , a joint venture between New York University and ��������Ƶ. The school, which also provides , is the only accelerated three-year MD program focused on primary care in New York State.

In 2024, a study by NYU Grossman School of Medicine researchers, published in Academic Medicine, found that the three-year graduates performed as well as or better than their peers across nearly all metrics. NYU Grossman School of Medicine’s success has inspired other institutions to adopt three-year medical degree programs. The school leads a consortium of more than 30 medical schools nationwide, funded by the Josiah Macy Jr. Foundation, to share best practices and expand the model.

Leaders in Research

��������Ƶ is one of the highest-funded health systems for research in the United States, with $1.1 billion in active awards from the National Institutes of Health (NIH). NYU Grossman School of Medicine is the fastest-growing research enterprise among the nation’s top 20 medical schools, and stands out as a highly productive, research-intensive institution, with more active awards per researcher than any other top-20 medical school.

Our team of over 1,000 investigators leads some of the most ambitious and transformative research in the nation, with active award funding per researcher currently exceeding that of any other top 20 medical school. In 2021, ��������Ƶ was selected by the NIH to be the Clinical Science Core of the Researching COVID to Enhance Recovery (RECOVER) Initiative and received a $450 million parent award, the largest NIH grant in history, to spearhead efforts to unravel long COVID. Since then, ��������Ƶ has successfully constructed the RECOVER Consortium, making multiple subawards to a network of lead investigators studying the long-term effects of COVID-19 at 33 institutions across the nation. These researchers coordinate data, monitor protocols, and guide communications with patients and clinicians.

In 2024, the NIH entrusted ��������Ƶ with nearly $31 million for dementia research at the , $20 million for the Perlmutter Cancer Center as part of its designation as one of only 49 Comprehensive Cancer Centers nationwide, and $7.8 million for ��������Ƶ Transplant Institute to pioneer innovative lung transplantation methods.